WASHINGTON, February 22, 2024 — The Department of Health and Human Services (HHS) has asked the Department of Justice to investigate Hims & Hers, a telehealth company, for potential federal law violations related to its plans to widely offer a compounded version of a low-cost weight loss pill, according to a social media post by HHS general counsel Mike Stuart.
FDA Signals Crackdown on Compounded Weight Loss Drugs
The Food and Drug Administration is preparing to restrict access to ingredients used in compounded versions of popular GLP-1 medications.
- The HHS request for a DOJ investigation centers on Hims & Hers’ plan to make a compounded weight loss drug readily available.
- The FDA announced it will take “decisive steps” to prevent the mass marketing of unapproved, compounded GLP-1 drugs.
- The agency intends to limit access to the active pharmaceutical ingredients needed to create these compounded medications.
This action follows an announcement from Hims & Hers regarding its intentions, prompting the FDA to respond swiftly. The FDA’s concern revolves around ensuring the quality, safety, and effectiveness of medications, particularly those produced through compounding pharmacies.
What are GLP-1 drugs? These medications, including those used for obesity and diabetes treatment, have gained significant attention for their potential weight loss benefits. Compounding pharmacies create customized versions of drugs, often when commercially manufactured options are unavailable or in short supply.
The FDA’s move aims to protect consumers from potentially harmful or ineffective drugs that haven’t undergone the agency’s rigorous approval process.
In a brief statement, the FDA stated it will “restrict the use” of active pharmaceutical ingredients that could be used in compounded versions of these drugs to “safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy.” The agency’s statement underscores its commitment to upholding pharmaceutical standards and protecting public health.
The Risks of Compounded Medications
While compounding pharmacies can play a vital role in providing customized medications, the FDA has expressed concerns about the potential risks associated with mass-produced, unapproved compounded drugs. These risks include inconsistent dosages, contamination, and the use of substandard ingredients.
The FDA’s actions signal a heightened scrutiny of the compounded drug market, particularly as demand for GLP-1 medications continues to rise. The agency’s goal is to strike a balance between providing access to necessary medications and ensuring patient safety.
